nky 722 has been researched along with nifedipine in 1 studies
Studies (nky 722) | Trials (nky 722) | Recent Studies (post-2010) (nky 722) | Studies (nifedipine) | Trials (nifedipine) | Recent Studies (post-2010) (nifedipine) |
---|---|---|---|---|---|
12 | 0 | 0 | 16,024 | 2,496 | 1,505 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fukata, F; Kanda, M; Kurahashi, K; Matsui, H; Nakamura, S; Shirahase, H; Wada, K | 1 |
1 other study(ies) available for nky 722 and nifedipine
Article | Year |
---|---|
Effects of the novel water-soluble calcium antagonist (+/-)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the responses of isolated canine arteries.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Animals; Arteries; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Dihydropyridines; Dogs; Female; In Vitro Techniques; Male; Muscle Relaxation; Muscle, Smooth, Vascular; Nicardipine; Nifedipine; Norepinephrine; Potassium Chloride; Vasoconstrictor Agents; Vasodilator Agents | 1995 |